CN104768573A - 用于位点特异性uPAR靶向的177-Lu标记肽 - Google Patents
用于位点特异性uPAR靶向的177-Lu标记肽 Download PDFInfo
- Publication number
- CN104768573A CN104768573A CN201380032450.2A CN201380032450A CN104768573A CN 104768573 A CN104768573 A CN 104768573A CN 201380032450 A CN201380032450 A CN 201380032450A CN 104768573 A CN104768573 A CN 104768573A
- Authority
- CN
- China
- Prior art keywords
- ser
- phe
- alanine
- cyclohexyl
- upar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201200321 | 2012-05-08 | ||
DKPA201200321 | 2012-05-08 | ||
PCT/DK2013/050126 WO2013167130A1 (en) | 2012-05-08 | 2013-05-03 | 177-Lu LABELED PEPTIDE FOR SITE-SPECIFIC uPAR-TARGETING |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104768573A true CN104768573A (zh) | 2015-07-08 |
CN104768573B CN104768573B (zh) | 2017-08-29 |
Family
ID=49550163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380032450.2A Active CN104768573B (zh) | 2012-05-08 | 2013-05-03 | 用于位点特异性uPAR靶向的177‑Lu标记肽 |
Country Status (7)
Country | Link |
---|---|
US (2) | US10994032B2 (zh) |
EP (1) | EP2846826B1 (zh) |
JP (2) | JP2015532636A (zh) |
CN (1) | CN104768573B (zh) |
CA (1) | CA2905172C (zh) |
HK (1) | HK1212219A1 (zh) |
WO (1) | WO2013167130A1 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10994032B2 (en) * | 2012-05-08 | 2021-05-04 | Trt Innovations Aps | 177-Lu labeled peptide for site-specific uPAR-targeting |
CA2903261C (en) * | 2012-12-03 | 2021-03-09 | Curasight Aps | Positron emitting radionuclide labeled peptides for human upar pet imaging |
CA2961095C (en) | 2014-09-17 | 2021-02-09 | Rigshospitalet | Upar targeting peptide for use in perioperative optical imaging of invasive cancer |
KR20190003722A (ko) | 2016-05-02 | 2019-01-09 | 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 분자 영상화를 위한 이량체화 전략 및 화합물 및/또는 방사선 면역요법 |
US11951168B2 (en) * | 2016-08-19 | 2024-04-09 | Perseus Proteomics Inc. | Composition containing buffer |
US20190358351A1 (en) * | 2016-11-17 | 2019-11-28 | Minerva Imaging Aps | 177-lu labeled active site inhibited factor vii |
JP7487110B2 (ja) * | 2018-04-05 | 2024-05-20 | フュージョン ファーマシューティカルズ インコーポレイテッド | Hsp90標的化コンジュゲート及びその製剤 |
US10596276B2 (en) | 2018-07-25 | 2020-03-24 | Advanced Accelerator Applications (Italy) S.R.L. | Stable, concentrated radionuclide complex solutions |
US10596278B2 (en) | 2018-07-25 | 2020-03-24 | Advanced Accelerator Applications (Italy) S.R.L. | Stable, concentrated radionuclide complex solutions |
CA3200503A1 (en) | 2020-12-01 | 2022-06-09 | Andreas Kjaer | Urokinase plasminogen activator receptor targeted radiolabeled peptide conjugates |
WO2023173074A2 (en) * | 2022-03-10 | 2023-09-14 | The Research Foundation For The State University Of New York | Immunostimulant-cytotoxic conjugate composition and methods for cancer treatment |
CN114874308B (zh) * | 2022-05-26 | 2023-02-17 | 苏州大学 | 一种核素标记的抑制肽及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101065152A (zh) * | 2004-09-29 | 2007-10-31 | 通用电气医疗集团股份有限公司 | 靶向尿激酶纤溶酶原激活物受体的造影剂 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444690A (en) | 1982-02-25 | 1984-04-24 | University Patents, Inc. | Technetium chelates |
US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
US5120526A (en) | 1985-01-14 | 1992-06-09 | Neorx Corporation | Method of producing metal radionuclide labeled proteins for diagnosis and therapy |
US4861869A (en) | 1986-05-29 | 1989-08-29 | Mallinckrodt, Inc. | Coupling agents for joining radionuclide metal ions with biologically useful proteins |
US4965392A (en) | 1987-03-26 | 1990-10-23 | Neorx Corporation | Chelating compounds for metal-radionuclide labeled proteins |
US5175257A (en) | 1989-12-29 | 1992-12-29 | Neorx Corporation | Radiolabeled proteins for diagnostic or therapeutic use |
US5310536A (en) | 1992-02-06 | 1994-05-10 | Mallinckrodt Medical, Inc. | Ligands for improving metal chelate formation kinetics |
US5830431A (en) * | 1995-06-07 | 1998-11-03 | Mallinckrodt Medical, Inc. | Radiolabeled peptide compositions for site-specific targeting |
US6277818B1 (en) | 1998-10-29 | 2001-08-21 | Angstrom Pharmaceuticals, Inc. | Cyclic peptide ligands that target urokinase plasminogen activator receptor |
US5942492A (en) | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
AR020101A1 (es) | 1998-07-01 | 2002-04-10 | Cancerforskingsfonden Af 1989 | Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado. |
CA2406882A1 (en) | 1999-10-01 | 2001-04-12 | Angstrom Pharmaceuticals, Inc. | Diagnostic probes and therapeutics targeting upa and upar |
WO2007044892A2 (en) * | 2005-10-10 | 2007-04-19 | American Diagnostica, Inc. | Upar-binding molecule-drug conjugates and uses thereof |
WO2007134274A2 (en) * | 2006-05-12 | 2007-11-22 | Attenuon, Llc | Antibodies to urokinase- type plasminogen activator receptor(upar)bind cancer stem cells: use in diagnosis and therapy |
ES2732823T3 (es) * | 2011-08-31 | 2019-11-26 | Somscan Aps | Trazador Pet para imágenes de tumores neuroendocrinos |
US10994032B2 (en) * | 2012-05-08 | 2021-05-04 | Trt Innovations Aps | 177-Lu labeled peptide for site-specific uPAR-targeting |
CA2903261C (en) * | 2012-12-03 | 2021-03-09 | Curasight Aps | Positron emitting radionuclide labeled peptides for human upar pet imaging |
CA2961095C (en) * | 2014-09-17 | 2021-02-09 | Rigshospitalet | Upar targeting peptide for use in perioperative optical imaging of invasive cancer |
-
2013
- 2013-05-03 US US14/399,820 patent/US10994032B2/en active Active
- 2013-05-03 CA CA2905172A patent/CA2905172C/en active Active
- 2013-05-03 EP EP13788361.7A patent/EP2846826B1/en active Active
- 2013-05-03 JP JP2015510647A patent/JP2015532636A/ja active Pending
- 2013-05-03 WO PCT/DK2013/050126 patent/WO2013167130A1/en active Application Filing
- 2013-05-03 CN CN201380032450.2A patent/CN104768573B/zh active Active
-
2016
- 2016-01-07 HK HK16100118.9A patent/HK1212219A1/zh unknown
-
2019
- 2019-01-17 JP JP2019005811A patent/JP6814234B2/ja active Active
-
2021
- 2021-01-07 US US17/144,067 patent/US20210236666A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101065152A (zh) * | 2004-09-29 | 2007-10-31 | 通用电气医疗集团股份有限公司 | 靶向尿激酶纤溶酶原激活物受体的造影剂 |
Non-Patent Citations (1)
Title |
---|
KNOR S ET AL.: "Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in a-emitter therapy for disseminated ovarian cancer", 《EUR J NUCL MED MOL IMAGING》 * |
Also Published As
Publication number | Publication date |
---|---|
US20210236666A1 (en) | 2021-08-05 |
WO2013167130A1 (en) | 2013-11-14 |
EP2846826B1 (en) | 2018-07-25 |
EP2846826A4 (en) | 2015-12-23 |
JP2015532636A (ja) | 2015-11-12 |
CA2905172A1 (en) | 2013-11-14 |
CA2905172C (en) | 2021-07-20 |
EP2846826A1 (en) | 2015-03-18 |
JP6814234B2 (ja) | 2021-01-13 |
JP2019077712A (ja) | 2019-05-23 |
US10994032B2 (en) | 2021-05-04 |
CN104768573B (zh) | 2017-08-29 |
US20150132219A1 (en) | 2015-05-14 |
HK1212219A1 (zh) | 2016-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104768573B (zh) | 用于位点特异性uPAR靶向的177‑Lu标记肽 | |
Shi et al. | Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging | |
Liu | Radiolabeled cyclic RGD peptide bioconjugates as radiotracers targeting multiple integrins | |
Jackson et al. | Clinical applications of radiolabeled peptides for PET | |
Garrison et al. | Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN (7− 14) NH2 structural paradigm in a prostate cancer model | |
Persson et al. | New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts | |
Gnanasegaran et al. | Molecular imaging agents for SPECT (and SPECT/CT) | |
Liu et al. | Development of RGD-based radiotracers for tumor imaging and therapy: translating from bench to bedside | |
Shi et al. | PET imaging of neovascularization with 68Ga-3PRGD2 for assessing tumor early response to Endostar antiangiogenic therapy | |
Zhao et al. | Development of a 99mTc-labeled single-domain antibody for SPECT/CT assessment of HER2 expression in breast cancer | |
Mitran et al. | Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26 | |
Guo et al. | Metastatic melanoma imaging with an 111In-labeled lactam bridge-cyclized α-melanocyte-stimulating hormone peptide | |
Ho et al. | Molecular Imaging, Pharmacokinetics, and Dosimetry of 111In‐AMBA in Human Prostate Tumor‐Bearing Mice | |
Ueda et al. | Synthesis and evaluation of a radioiodinated peptide probe targeting αvβ6 integrin for the detection of pancreatic ductal adenocarcinoma | |
Lv et al. | Promising potential of a 18F-labelled small-molecular radiotracer to evaluate PD-L1 expression in tumors by PET imaging | |
Luo et al. | An integrin alpha 6-targeted radiotracer with improved receptor binding affinity and tumor uptake | |
Ding et al. | 86Y-labeled albumin-binding fibroblast activation protein inhibitor for late-time-point cancer diagnosis | |
Stahl et al. | Positron emission tomography as a tool for translational research in oncology | |
Wen et al. | Synergism of 64Cu-labeled RGD with anti-PD-L1 immunotherapy for the long-acting antitumor effect | |
Ruan et al. | A simple kit formulation for preparation and exploratory human studies of a novel 99mTc-labeled fibroblast activation protein inhibitor tracer for Imaging of the fibroblast activation protein in cancers | |
Qin et al. | In vivo near-infrared fluorescence and SPECT-CT imaging of colorectal Cancer using the bradykinin B2R-specific ligand icatibant | |
Holland et al. | Copper-64 radiopharmaceuticals for oncologic imaging | |
Chen et al. | An overview of current advances of PD-L1 targeting immuno-imaging in cancers | |
Zhao et al. | An integrin-αvβ6/α5β1-bitargeted probe for the SPECT imaging of pancreatic adenocarcinoma in preclinical and primary clinical studies | |
Sogawa et al. | C-kit-targeted imaging of gastrointestinal stromal tumor using radiolabeled anti-c-kit monoclonal antibody in a mouse tumor model |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1212219 Country of ref document: HK |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20170717 Address after: Copenhagen Applicant after: TRT Innovations Ltd Address before: Copenhagen Applicant before: National Hospital |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1212219 Country of ref document: HK |